- Hepatitis B vaccination and immunotherapies: an update
-
Stasi C, Silvestri , Voller F
- KMID: 2470832
- Clin Exp Vaccine Res.
- 2020 Jan;9(1):1-7.
- doi: 10.7774/cevr.2020.9.1.1
World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)... -
- CITED
-
- Close
- SHARE
-
- Close
- Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
-
Kim SU, Jeon MY, Lim TS
- KMID: 2469909
- Korean J Gastroenterol.
- 2019 Dec;74(6):341-348.
- doi: 10.4166/kjg.2019.74.6.341
BACKGROUND/AIMS: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B
-
Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU
- KMID: 2467249
- Clin Mol Hepatol.
- 2019 Dec;25(4):390-399.
- doi: 10.3350/cmh.2018.0103
BACKGROUND/AIMS: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (Rad(CT) score) in patients with chronic hepatitis B (CHB)-related cirrhosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand
-
Laiwatthanapaisan R, Sripongpun P, Chamroonkul N, Dechaphunkul A, Sathitruangsak C, Sakdejayont S, Kongkamol , Piratvisuth T
- KMID: 2467246
- Clin Mol Hepatol.
- 2019 Dec;25(4):366-373.
- doi: 10.3350/cmh.2018.0111
BACKGROUND/AIMS: Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited.... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B
-
Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY
- KMID: 2463800
- Yonsei Med J.
- 2019 Dec;60(12):1203-1208.
- doi: 10.3349/ymj.2019.60.12.1203
Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was... -
- CITED
-
- Close
- SHARE
-
- Close
- New Biomarkers of Chronic Hepatitis B
-
Mak LY, Seto WK, Fung J, Yuen MF
- KMID: 2464306
- Gut Liver.
- 2019 Nov;13(6):589-595.
- doi: 10.5009/gnl18425
Chronic hepatitis B (CHB) infection leads to clinically heterogeneous disease outcomes. Different viral markers are utilized to monitor treatment effects and predict risk of complications in patients with CHB. Hepatitis... -
- CITED
-
- Close
- SHARE
-
- Close
- New Potential Therapies for Chronic Hepatitis B
-
Yoo SH, Kwon JH
- KMID: 2464185
- Korean J Gastroenterol.
- 2019 Nov;74(5):267-273.
- doi: 10.4166/kjg.2019.74.5.267
A HBV infection is a dynamic disease and long-term liver inflammation contributes to the development of liver cirrhosis and hepatocellular carcinoma. Currently available nucleos(t)ide analogues and pegylated interferon are effective... -
- CITED
-
- Close
- SHARE
-
- Close
- Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients
-
Yoon EL
- KMID: 2464184
- Korean J Gastroenterol.
- 2019 Nov;74(5):258-266.
- doi: 10.4166/kjg.2019.74.5.258
Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently... -
- CITED
-
- Close
- SHARE
-
- Close
- Long Term Efficacy of Antiviral Therapy: Mortality and Incidence of Hepatocellular Carcinoma
-
Lee HW
- KMID: 2464183
- Korean J Gastroenterol.
- 2019 Nov;74(5):251-257.
- doi: 10.4166/kjg.2019.74.5.251
Multiple studies have shown that oral antiviral therapies reduced the incidence of hepatocellular carcinoma (HCC) and improved the survival of patients with chronic hepatitis B when compared with that of... -
- CITED
-
- Close
- SHARE
-
- Close
- Natural History and Treatment Indications of Chronic Hepatitis B
-
Sinn DH
- KMID: 2464182
- Korean J Gastroenterol.
- 2019 Nov;74(5):245-250.
- doi: 10.4166/kjg.2019.74.5.245
HBV is the most common etiology of both liver cirrhosis and hepatocellular carcinoma in Korea. Despite much progress made, the currently available antiviral therapies cannot eradicate or eliminate this virus.... -
- CITED
-
- Close
- SHARE
-
- Close
- A case report of bleeding from duodenal varices treated with percutaneous transhepatic obliteration
-
Lee JH, Kim TH, Choi JW, Kim SY, Choi JY, Lee CK, Park BK, Chung JB
- KMID: 2464711
- Int J Gastrointest Interv.
- 2019 Oct;8(4):174-177.
- doi: 10.18528/ijgii190002
Duodenal varices are ectopic in nature and account for 40% of all ectopic bleeding cases. Ectopic variceal bleeding is rare (1%–5% of all variceal bleeding cases). The three principle approaches... -
- CITED
-
- Close
- SHARE
-
- Close
- Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity
-
Wu S, Tu R, Liang X
- KMID: 2464512
- Ultrasonography.
- 2019 Oct;38(4):327-335.
- doi: 10.14366/usg.18071
PURPOSE: This study was conducted to investigate whether the presence of patchy echogenicity in the liver of patients with chronic hepatitis B (CHB) is predictive of liver stiffness. METHODS: A total... -
- CITED
-
- Close
- SHARE
-
- Close
- Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B
-
Choi EJ, Kim JH, Han MS
- KMID: 2458680
- Lab Med Online.
- 2019 Oct;9(4):210-217.
- doi: 10.3343/lmo.2019.9.4.210
BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims... -
- CITED
-
- Close
- SHARE
-
- Close
- Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
-
Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH
- KMID: 2463613
- J Liver Cancer.
- 2019 Sep;19(2):128-135.
- doi: 10.17998/jlc.19.2.128
BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury.... -
- CITED
-
- Close
- SHARE
-
- Close
- Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
-
Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU
- KMID: 2459790
- Clin Mol Hepatol.
- 2019 Sep;25(3):283-293.
- doi: 10.3350/cmh.2018.0054
BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)... -
- CITED
-
- Close
- SHARE
-
- Close
- How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
-
Yu JH, Lee JW
- KMID: 2459789
- Clin Mol Hepatol.
- 2019 Sep;25(3):280-282.
- doi: 10.3350/cmh.2018.0104
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?
-
Hanouneh I, Alkhouri N, Singal AG
- KMID: 2459787
- Clin Mol Hepatol.
- 2019 Sep;25(3):264-269.
- doi: 10.3350/cmh.2019.1001
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available... -
- CITED
-
- Close
- SHARE
-
- Close
- The epidemiology of hepatitis B virus infection in Korea
-
Yim SY, Kim JH
- KMID: 2457016
- Korean J Intern Med.
- 2019 Sep;34(5):945-953.
- doi: 10.3904/kjim.2019.007
The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The... -
- CITED
-
- Close
- SHARE
-
- Close
- 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
-
Korean Liver Cancer Association (KLCA), National Cancer Center (NCC), Goyang, Korea
- KMID: 2467021
- Korean J Radiol.
- 2019 Jul;20(7):1042-1113.
- doi: 10.3348/kjr.2019.0140
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice
-
Song JE, Lee CH, Kim BS
- KMID: 2457310
- Korean J Intern Med.
- 2019 Jul;34(4):802-810.
- doi: 10.3904/kjim.2019.037
BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of... -
- CITED
-
- Close
- SHARE
-
- Close
